Neurogene Inc.
NASDAQ:NGNEBiotechnology
+$0.76 today
- Market cap
- $365.67M
- Beta
- 2.04
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$4.42
Volume 0.25M
Average 0.16M
NGNE Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Neurogene Inc.NASDAQ: NGNE
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $854K rose 12.1% year over year, ahead of the +0.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +12.1% holds above the trailing-twelve-month pace of +0.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.09M USD
- Year-over-year change
- -4.8%
- 4-year CAGR
- +34.4%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.09M | -4.8% |
| FY2024 | 2024-12-31 | 3.25M | -1.5% |
| FY2023 | 2023-12-31 | 3.3M | +3.2% |
| FY2022 | 2022-12-31 | 3.2M | +237.5% |
| FY2021 | 2021-12-31 | 947K | — |
Depreciation & Amortization vs competitors
How NGNE compares with its peers on the latest reported figures
- NGNE's LTM Mar 2026 depreciation & amortization of $3.18M is the 5th highest of the 8 companies compared; the peer median is $3.98M.
- Its year-over-year change of +0.0% is the 7th highest of 8, against a peer median of +2.6%.
- Over three fiscal years its annual growth of -1.1% compares with a peer median of +10.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.82M | +2.6% | +13.6% | 16.1% | |
| LTM Mar 2026 | $8.8M | +4.8% | +4.5% | 47.8% | |
| LTM Mar 2026 | $6.46M | +0.4% | +46.9% | 7.3% | |
| LTM Mar 2026 | $3.98M | -12.6% | -13.1% | 10.9% | |
| LTM Mar 2026 | $3.18M | +0.0% | -1.1% | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $2.12M | +4.8% | +22.0% | — |
| LTM Jun 2026 | $1.28M | +10.5% | -22.8% | 23.3% | |
| LTM Mar 2026 | $620K | +1.3% | +10.1% | — | |
| Peer median (excluding NGNE) | $3.98M | +2.6% | +10.1% | 16.1% | |
Competitors are the stored peer set for NGNE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 925K | 0 |
| Cost of Revenue | 42.26M | 3.2M | 3.26M | 3.25M | 3.19M |
| Gross Profit | (42.26M) | (3.2M) | (3.26M) | (2.32M) | (3.19M) |
| Gross Margin | — | — | — | -251.0% | — |
| Research & Development | 42.26M | 47.51M | 44.39M | 60.92M | 75.01M |
| Selling, General & Admin | 8.27M | 9.01M | 11.19M | 22.61M | 25.13M |
| Operating Expenses | 8.27M | 53.32M | 52.32M | 80.28M | 100.02M |
| Depreciation & Amortization | 947K | 3.2M | 3.3M | 3.25M | 3.09M |
| EBITDA | (49.57M) | (51.99M) | (33.01M) | (71.89M) | (87.25M) |
| EBITDA Margin | — | — | — | -7771.4% | — |
| Operating Income | (50.53M) | (56.52M) | (55.58M) | (82.61M) | (103.21M) |
| Operating Margin | — | — | — | -8930.3% | — |
| Interest Income | 19K | 1.34M | 2.95M | 8.47M | 11.55M |
| Interest Expense | 0 | 2K | 12K | 12K | 5K |
| Other Income / Expenses | 17K | 1.33M | 19.27M | 7.46M | 12.86M |
| Income Before Tax | (50.52M) | (55.19M) | (36.32M) | (75.14M) | (90.35M) |
| Pre-Tax Margin | — | — | — | -8123.7% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.52M) | (55.19M) | (36.32M) | (75.14M) | (90.35M) |
| Net Margin | — | — | — | -8123.7% | — |
| EPS (Basic) | (0.92) | (4.30) | (2.83) | (4.28) | (4.24) |
| EPS (Diluted) | (0.92) | (4.30) | (2.83) | (4.28) | (4.24) |
| Weighted Avg Shares | 55.04M | 12.82M | 12.82M | 17.57M | 21.17M |
| Weighted Avg Shares (Diluted) | 55.04M | 12.82M | 12.82M | 17.57M | 21.17M |
Neurogene Inc.
NASDAQ:NGNE
Intrinsic Alpha fair value
Locked
Current Price
$23.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.